1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Liver Transplantation Operation
        1.2.3 UDCA Drugs
        1.2.4 PSC Drugs
    1.3 Market by Application
        1.3.1 Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Hospital
        1.3.3 Clinics
        1.3.4 Other
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Primary Sclerosing Cholangitis Treatment Market Perspective (2017-2028)
    2.2 Primary Sclerosing Cholangitis Treatment Growth Trends by Region
        2.2.1 Primary Sclerosing Cholangitis Treatment Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Primary Sclerosing Cholangitis Treatment Historic Market Size by Region (2017-2022)
        2.2.3 Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Region (2023-2028)
    2.3 Primary Sclerosing Cholangitis Treatment Market Dynamics
        2.3.1 Primary Sclerosing Cholangitis Treatment Industry Trends
        2.3.2 Primary Sclerosing Cholangitis Treatment Market Drivers
        2.3.3 Primary Sclerosing Cholangitis Treatment Market Challenges
        2.3.4 Primary Sclerosing Cholangitis Treatment Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Primary Sclerosing Cholangitis Treatment Players by Revenue
        3.1.1 Global Top Primary Sclerosing Cholangitis Treatment Players by Revenue (2017-2022)
        3.1.2 Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Players (2017-2022)
    3.2 Global Primary Sclerosing Cholangitis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Primary Sclerosing Cholangitis Treatment Revenue
    3.4 Global Primary Sclerosing Cholangitis Treatment Market Concentration Ratio
        3.4.1 Global Primary Sclerosing Cholangitis Treatment Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Primary Sclerosing Cholangitis Treatment Revenue in 2021
    3.5 Primary Sclerosing Cholangitis Treatment Key Players Head office and Area Served
    3.6 Key Players Primary Sclerosing Cholangitis Treatment Product Solution and Service
    3.7 Date of Enter into Primary Sclerosing Cholangitis Treatment Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Primary Sclerosing Cholangitis Treatment Breakdown Data by Type
    4.1 Global Primary Sclerosing Cholangitis Treatment Historic Market Size by Type (2017-2022)
    4.2 Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Type (2023-2028)
5 Primary Sclerosing Cholangitis Treatment Breakdown Data by Application
    5.1 Global Primary Sclerosing Cholangitis Treatment Historic Market Size by Application (2017-2022)
    5.2 Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Primary Sclerosing Cholangitis Treatment Market Size (2017-2028)
    6.2 North America Primary Sclerosing Cholangitis Treatment Market Size by Type
        6.2.1 North America Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022)
        6.2.2 North America Primary Sclerosing Cholangitis Treatment Market Size by Type (2023-2028)
        6.2.3 North America Primary Sclerosing Cholangitis Treatment Market Share by Type (2017-2028)
    6.3 North America Primary Sclerosing Cholangitis Treatment Market Size by Application
        6.3.1 North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022)
        6.3.2 North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2023-2028)
        6.3.3 North America Primary Sclerosing Cholangitis Treatment Market Share by Application (2017-2028)
    6.4 North America Primary Sclerosing Cholangitis Treatment Market Size by Country
        6.4.1 North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022)
        6.4.2 North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Primary Sclerosing Cholangitis Treatment Market Size (2017-2028)
    7.2 Europe Primary Sclerosing Cholangitis Treatment Market Size by Type
        7.2.1 Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022)
        7.2.2 Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2023-2028)
        7.2.3 Europe Primary Sclerosing Cholangitis Treatment Market Share by Type (2017-2028)
    7.3 Europe Primary Sclerosing Cholangitis Treatment Market Size by Application
        7.3.1 Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022)
        7.3.2 Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2023-2028)
        7.3.3 Europe Primary Sclerosing Cholangitis Treatment Market Share by Application (2017-2028)
    7.4 Europe Primary Sclerosing Cholangitis Treatment Market Size by Country
        7.4.1 Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022)
        7.4.2 Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size (2017-2028)
    8.2 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Type
        8.2.1 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Share by Type (2017-2028)
    8.3 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Application
        8.3.1 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Share by Application (2017-2028)
    8.4 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Region
        8.4.1 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Primary Sclerosing Cholangitis Treatment Market Size (2017-2028)
    9.2 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Type
        9.2.1 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022)
        9.2.2 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Type (2023-2028)
        9.2.3 Latin America Primary Sclerosing Cholangitis Treatment Market Share by Type (2017-2028)
    9.3 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application
        9.3.1 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022)
        9.3.2 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application (2023-2028)
        9.3.3 Latin America Primary Sclerosing Cholangitis Treatment Market Share by Application (2017-2028)
    9.4 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country
        9.4.1 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022)
        9.4.2 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size (2017-2028)
    10.2 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Type
        10.2.1 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Share by Type (2017-2028)
    10.3 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Application
        10.3.1 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Share by Application (2017-2028)
    10.4 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Country
        10.4.1 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Allergan
        11.1.1 Allergan Company Details
        11.1.2 Allergan Business Overview
        11.1.3 Allergan Primary Sclerosing Cholangitis Treatment Introduction
        11.1.4 Allergan Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
        11.1.5 Allergan Recent Developments
    11.2 Glenmark
        11.2.1 Glenmark Company Details
        11.2.2 Glenmark Business Overview
        11.2.3 Glenmark Primary Sclerosing Cholangitis Treatment Introduction
        11.2.4 Glenmark Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
        11.2.5 Glenmark Recent Developments
    11.3 Impax Laboratories
        11.3.1 Impax Laboratories Company Details
        11.3.2 Impax Laboratories Business Overview
        11.3.3 Impax Laboratories Primary Sclerosing Cholangitis Treatment Introduction
        11.3.4 Impax Laboratories Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
        11.3.5 Impax Laboratories Recent Developments
    11.4 Mylan
        11.4.1 Mylan Company Details
        11.4.2 Mylan Business Overview
        11.4.3 Mylan Primary Sclerosing Cholangitis Treatment Introduction
        11.4.4 Mylan Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
        11.4.5 Mylan Recent Developments
    11.5 Teva Pharmaceuticals
        11.5.1 Teva Pharmaceuticals Company Details
        11.5.2 Teva Pharmaceuticals Business Overview
        11.5.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
        11.5.4 Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
        11.5.5 Teva Pharmaceuticals Recent Developments
    11.6 Dr. Falk Pharma
        11.6.1 Dr. Falk Pharma Company Details
        11.6.2 Dr. Falk Pharma Business Overview
        11.6.3 Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Introduction
        11.6.4 Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
        11.6.5 Dr. Falk Pharma Recent Developments
    11.7 Daewoong Pharmaceutical
        11.7.1 Daewoong Pharmaceutical Company Details
        11.7.2 Daewoong Pharmaceutical Business Overview
        11.7.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Introduction
        11.7.4 Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
        11.7.5 Daewoong Pharmaceutical Recent Developments
    11.8 Epic Pharma
        11.8.1 Epic Pharma Company Details
        11.8.2 Epic Pharma Business Overview
        11.8.3 Epic Pharma Primary Sclerosing Cholangitis Treatment Introduction
        11.8.4 Epic Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
        11.8.5 Epic Pharma Recent Developments
    11.9 Mitsubishi Tanabe Pharma
        11.9.1 Mitsubishi Tanabe Pharma Company Details
        11.9.2 Mitsubishi Tanabe Pharma Business Overview
        11.9.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Introduction
        11.9.4 Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
        11.9.5 Mitsubishi Tanabe Pharma Recent Developments
    11.10 Lannett
        11.10.1 Lannett Company Details
        11.10.2 Lannett Business Overview
        11.10.3 Lannett Primary Sclerosing Cholangitis Treatment Introduction
        11.10.4 Lannett Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
        11.10.5 Lannett Recent Developments
    11.11 Bruschettini
        11.11.1 Bruschettini Company Details
        11.11.2 Bruschettini Business Overview
        11.11.3 Bruschettini Primary Sclerosing Cholangitis Treatment Introduction
        11.11.4 Bruschettini Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
        11.11.5 Bruschettini Recent Developments
    11.12 Shanghai Pharma
        11.12.1 Shanghai Pharma Company Details
        11.12.2 Shanghai Pharma Business Overview
        11.12.3 Shanghai Pharma Primary Sclerosing Cholangitis Treatment Introduction
        11.12.4 Shanghai Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
        11.12.5 Shanghai Pharma Recent Developments
    11.13 Grindeks
        11.13.1 Grindeks Company Details
        11.13.2 Grindeks Business Overview
        11.13.3 Grindeks Primary Sclerosing Cholangitis Treatment Introduction
        11.13.4 Grindeks Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
        11.13.5 Grindeks Recent Developments
    11.14 Acorda Therapeutics
        11.14.1 Acorda Therapeutics Company Details
        11.14.2 Acorda Therapeutics Business Overview
        11.14.3 Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Introduction
        11.14.4 Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
        11.14.5 Acorda Therapeutics Recent Developments
    11.15 Gilead Sciences
        11.15.1 Gilead Sciences Company Details
        11.15.2 Gilead Sciences Business Overview
        11.15.3 Gilead Sciences Primary Sclerosing Cholangitis Treatment Introduction
        11.15.4 Gilead Sciences Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
        11.15.5 Gilead Sciences Recent Developments
    11.16 Intercept Pharmaceuticals
        11.16.1 Intercept Pharmaceuticals Company Details
        11.16.2 Intercept Pharmaceuticals Business Overview
        11.16.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
        11.16.4 Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
        11.16.5 Intercept Pharmaceuticals Recent Developments
    11.17 Shire Plc
        11.17.1 Shire Plc Company Details
        11.17.2 Shire Plc Business Overview
        11.17.3 Shire Plc Primary Sclerosing Cholangitis Treatment Introduction
        11.17.4 Shire Plc Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
        11.17.5 Shire Plc Recent Developments
    11.18 NGM Biopharmaceuticals
        11.18.1 NGM Biopharmaceuticals Company Details
        11.18.2 NGM Biopharmaceuticals Business Overview
        11.18.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
        11.18.4 NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
        11.18.5 NGM Biopharmaceuticals Recent Developments
    11.19 Conatus Pharmaceuticals
        11.19.1 Conatus Pharmaceuticals Company Details
        11.19.2 Conatus Pharmaceuticals Business Overview
        11.19.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
        11.19.4 Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
        11.19.5 Conatus Pharmaceuticals Recent Developments
    11.20 Durect Corporation
        11.20.1 Durect Corporation Company Details
        11.20.2 Durect Corporation Business Overview
        11.20.3 Durect Corporation Primary Sclerosing Cholangitis Treatment Introduction
        11.20.4 Durect Corporation Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
        11.20.5 Durect Corporation Recent Developments
    11.21 Sirnaomics
        11.21.1 Sirnaomics Company Details
        11.21.2 Sirnaomics Business Overview
        11.21.3 Sirnaomics Primary Sclerosing Cholangitis Treatment Introduction
        11.21.4 Sirnaomics Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
        11.21.5 Sirnaomics Recent Developments
    11.22 Shenzhen HighTide Biopharmaceuticals
        11.22.1 Shenzhen HighTide Biopharmaceuticals Company Details
        11.22.2 Shenzhen HighTide Biopharmaceuticals Business Overview
        11.22.3 Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
        11.22.4 Shenzhen HighTide Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
        11.22.5 Shenzhen HighTide Biopharmaceuticals Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Liver Transplantation Operation
    Table 3. Key Players of UDCA Drugs
    Table 4. Key Players of PSC Drugs
    Table 5. Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 6. Global Primary Sclerosing Cholangitis Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 7. Global Primary Sclerosing Cholangitis Treatment Market Size by Region (2017-2022) & (US$ Million)
    Table 8. Global Primary Sclerosing Cholangitis Treatment Market Share by Region (2017-2022)
    Table 9. Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 10. Global Primary Sclerosing Cholangitis Treatment Market Share by Region (2023-2028)
    Table 11. Primary Sclerosing Cholangitis Treatment Market Trends
    Table 12. Primary Sclerosing Cholangitis Treatment Market Drivers
    Table 13. Primary Sclerosing Cholangitis Treatment Market Challenges
    Table 14. Primary Sclerosing Cholangitis Treatment Market Restraints
    Table 15. Global Primary Sclerosing Cholangitis Treatment Revenue by Players (2017-2022) & (US$ Million)
    Table 16. Global Primary Sclerosing Cholangitis Treatment Revenue Share by Players (2017-2022)
    Table 17. Global Top Primary Sclerosing Cholangitis Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Sclerosing Cholangitis Treatment as of 2021)
    Table 18. Ranking of Global Top Primary Sclerosing Cholangitis Treatment Companies by Revenue (US$ Million) in 2021
    Table 19. Global 5 Largest Players Market Share by Primary Sclerosing Cholangitis Treatment Revenue (CR5 and HHI) & (2017-2022)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Primary Sclerosing Cholangitis Treatment Product Solution and Service
    Table 22. Date of Enter into Primary Sclerosing Cholangitis Treatment Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 25. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Type (2017-2022)
    Table 26. Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 27. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Type (2023-2028)
    Table 28. Global Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 29. Global Primary Sclerosing Cholangitis Treatment Revenue Share by Application (2017-2022)
    Table 30. Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 31. Global Primary Sclerosing Cholangitis Treatment Revenue Share by Application (2023-2028)
    Table 32. North America Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 33. North America Primary Sclerosing Cholangitis Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 34. North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 35. North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 36. North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 37. North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 38. Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 39. Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 40. Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 41. Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 42. Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 43. Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 44. Asia Pacific Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 45. Asia Pacific Primary Sclerosing Cholangitis Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 46. Asia Pacific Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 47. Asia Pacific Primary Sclerosing Cholangitis Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 48. Asia Pacific Primary Sclerosing Cholangitis Treatment Market Size by Region (2017-2022) & (US$ Million)
    Table 49. Asia Pacific Primary Sclerosing Cholangitis Treatment Market Size by Region (2023-2028) & (US$ Million)
    Table 50. Latin America Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 51. Latin America Primary Sclerosing Cholangitis Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 52. Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 53. Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 54. Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 55. Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 56. Middle East and Africa Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022) & (US$ Million)
    Table 57. Middle East and Africa Primary Sclerosing Cholangitis Treatment Market Size by Type (2023-2028) & (US$ Million)
    Table 58. Middle East and Africa Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022) & (US$ Million)
    Table 59. Middle East and Africa Primary Sclerosing Cholangitis Treatment Market Size by Application (2023-2028) & (US$ Million)
    Table 60. Middle East and Africa Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022) & (US$ Million)
    Table 61. Middle East and Africa Primary Sclerosing Cholangitis Treatment Market Size by Country (2023-2028) & (US$ Million)
    Table 62. Allergan Company Details
    Table 63. Allergan Business Overview
    Table 64. Allergan Primary Sclerosing Cholangitis Treatment Product
    Table 65. Allergan Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
    Table 66. Allergan Recent Developments
    Table 67. Glenmark Company Details
    Table 68. Glenmark Business Overview
    Table 69. Glenmark Primary Sclerosing Cholangitis Treatment Product
    Table 70. Glenmark Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
    Table 71. Glenmark Recent Developments
    Table 72. Impax Laboratories Company Details
    Table 73. Impax Laboratories Business Overview
    Table 74. Impax Laboratories Primary Sclerosing Cholangitis Treatment Product
    Table 75. Impax Laboratories Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
    Table 76. Impax Laboratories Recent Developments
    Table 77. Mylan Company Details
    Table 78. Mylan Business Overview
    Table 79. Mylan Primary Sclerosing Cholangitis Treatment Product
    Table 80. Mylan Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
    Table 81. Mylan Recent Developments
    Table 82. Teva Pharmaceuticals Company Details
    Table 83. Teva Pharmaceuticals Business Overview
    Table 84. Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product
    Table 85. Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
    Table 86. Teva Pharmaceuticals Recent Developments
    Table 87. Dr. Falk Pharma Company Details
    Table 88. Dr. Falk Pharma Business Overview
    Table 89. Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Product
    Table 90. Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
    Table 91. Dr. Falk Pharma Recent Developments
    Table 92. Daewoong Pharmaceutical Company Details
    Table 93. Daewoong Pharmaceutical Business Overview
    Table 94. Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Product
    Table 95. Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
    Table 96. Daewoong Pharmaceutical Recent Developments
    Table 97. Epic Pharma Company Details
    Table 98. Epic Pharma Business Overview
    Table 99. Epic Pharma Primary Sclerosing Cholangitis Treatment Product
    Table 100. Epic Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
    Table 101. Epic Pharma Recent Developments
    Table 102. Mitsubishi Tanabe Pharma Company Details
    Table 103. Mitsubishi Tanabe Pharma Business Overview
    Table 104. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Product
    Table 105. Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
    Table 106. Mitsubishi Tanabe Pharma Recent Developments
    Table 107. Lannett Company Details
    Table 108. Lannett Business Overview
    Table 109. Lannett Primary Sclerosing Cholangitis Treatment Product
    Table 110. Lannett Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
    Table 111. Lannett Recent Developments
    Table 112. Bruschettini Company Details
    Table 113. Bruschettini Business Overview
    Table 114. Bruschettini Primary Sclerosing Cholangitis Treatment Product
    Table 115. Bruschettini Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
    Table 116. Bruschettini Recent Developments
    Table 117. Shanghai Pharma Company Details
    Table 118. Shanghai Pharma Business Overview
    Table 119. Shanghai Pharma Primary Sclerosing Cholangitis Treatment Product
    Table 120. Shanghai Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
    Table 121. Shanghai Pharma Recent Developments
    Table 122. Grindeks Company Details
    Table 123. Grindeks Business Overview
    Table 124. Grindeks Primary Sclerosing Cholangitis Treatment Product
    Table 125. Grindeks Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
    Table 126. Grindeks Recent Developments
    Table 127. Acorda Therapeutics Company Details
    Table 128. Acorda Therapeutics Business Overview
    Table 129. Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Product
    Table 130. Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
    Table 131. Acorda Therapeutics Recent Developments
    Table 132. Gilead Sciences Company Details
    Table 133. Gilead Sciences Business Overview
    Table 134. Gilead Sciences Primary Sclerosing Cholangitis Treatment Product
    Table 135. Gilead Sciences Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
    Table 136. Gilead Sciences Recent Developments
    Table 137. Intercept Pharmaceuticals Company Details
    Table 138. Intercept Pharmaceuticals Business Overview
    Table 139. Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product
    Table 140. Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
    Table 141. Intercept Pharmaceuticals Recent Developments
    Table 142. Shire Plc Company Details
    Table 143. Shire Plc Business Overview
    Table 144. Shire Plc Primary Sclerosing Cholangitis Treatment Product
    Table 145. Shire Plc Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
    Table 146. Shire Plc Recent Developments
    Table 147. NGM Biopharmaceuticals Company Details
    Table 148. NGM Biopharmaceuticals Business Overview
    Table 149. NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product
    Table 150. NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
    Table 151. NGM Biopharmaceuticals Recent Developments
    Table 152. Conatus Pharmaceuticals Company Details
    Table 153. Conatus Pharmaceuticals Business Overview
    Table 154. Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product
    Table 155. Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
    Table 156. Conatus Pharmaceuticals Recent Developments
    Table 157. Durect Corporation Company Details
    Table 158. Durect Corporation Business Overview
    Table 159. Durect Corporation Primary Sclerosing Cholangitis Treatment Product
    Table 160. Durect Corporation Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
    Table 161. Durect Corporation Recent Developments
    Table 162. Sirnaomics Company Details
    Table 163. Sirnaomics Business Overview
    Table 164. Sirnaomics Primary Sclerosing Cholangitis Treatment Product
    Table 165. Sirnaomics Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
    Table 166. Sirnaomics Recent Developments
    Table 167. Shenzhen HighTide Biopharmaceuticals Company Details
    Table 168. Shenzhen HighTide Biopharmaceuticals Business Overview
    Table 169. Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product
    Table 170. Shenzhen HighTide Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
    Table 171. Shenzhen HighTide Biopharmaceuticals Recent Developments
    Table 172. Research Programs/Design for This Report
    Table 173. Key Data Information from Secondary Sources
    Table 174. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Primary Sclerosing Cholangitis Treatment Market Share by Type: 2021 VS 2028
    Figure 2. Liver Transplantation Operation Features
    Figure 3. UDCA Drugs Features
    Figure 4. PSC Drugs Features
    Figure 5. Global Primary Sclerosing Cholangitis Treatment Market Share by Application: 2021 VS 2028
    Figure 6. Hospital Case Studies
    Figure 7. Clinics Case Studies
    Figure 8. Other Case Studies
    Figure 9. Primary Sclerosing Cholangitis Treatment Report Years Considered
    Figure 10. Global Primary Sclerosing Cholangitis Treatment Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 11. Global Primary Sclerosing Cholangitis Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 12. Global Primary Sclerosing Cholangitis Treatment Market Share by Region: 2021 VS 2028
    Figure 13. Global Primary Sclerosing Cholangitis Treatment Market Share by Players in 2021
    Figure 14. Global Top Primary Sclerosing Cholangitis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Sclerosing Cholangitis Treatment as of 2021)
    Figure 15. The Top 10 and 5 Players Market Share by Primary Sclerosing Cholangitis Treatment Revenue in 2021
    Figure 16. North America Primary Sclerosing Cholangitis Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 17. North America Primary Sclerosing Cholangitis Treatment Market Size Market Share by Type (2017-2028)
    Figure 18. North America Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application (2017-2028)
    Figure 19. North America Primary Sclerosing Cholangitis Treatment Market Size Share by Country (2017-2028)
    Figure 20. United States Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 21. Canada Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. Europe Primary Sclerosing Cholangitis Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 23. Europe Primary Sclerosing Cholangitis Treatment Market Size Market Share by Type (2017-2028)
    Figure 24. Europe Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application (2017-2028)
    Figure 25. Europe Primary Sclerosing Cholangitis Treatment Market Size Share by Country (2017-2028)
    Figure 26. Germany Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. France Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. U.K. Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Italy Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Russia Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Nordic Countries Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 33. Asia Pacific Primary Sclerosing Cholangitis Treatment Market Size Market Share by Type (2017-2028)
    Figure 34. Asia Pacific Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application (2017-2028)
    Figure 35. Asia Pacific Primary Sclerosing Cholangitis Treatment Market Size Share by Region (2017-2028)
    Figure 36. China Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. Japan Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. South Korea Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. India Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Australia Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 42. Latin America Primary Sclerosing Cholangitis Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 43. Latin America Primary Sclerosing Cholangitis Treatment Market Size Market Share by Type (2017-2028)
    Figure 44. Latin America Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application (2017-2028)
    Figure 45. Latin America Primary Sclerosing Cholangitis Treatment Market Size Share by Country (2017-2028)
    Figure 46. Mexico Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 47. Brazil Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 48. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size YoY (2017-2028) & (US$ Million)
    Figure 49. Middle East and Africa Primary Sclerosing Cholangitis Treatment Market Size Market Share by Type (2017-2028)
    Figure 50. Middle East and Africa Primary Sclerosing Cholangitis Treatment Market Size Market Share by Application (2017-2028)
    Figure 51. Middle East and Africa Primary Sclerosing Cholangitis Treatment Market Size Share by Country (2017-2028)
    Figure 52. Turkey Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 53. Saudi Arabia Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 54. UAE Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 55. Allergan Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
    Figure 56. Glenmark Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
    Figure 57. Impax Laboratories Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
    Figure 58. Mylan Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
    Figure 59. Teva Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
    Figure 60. Dr. Falk Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
    Figure 61. Daewoong Pharmaceutical Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
    Figure 62. Epic Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
    Figure 63. Mitsubishi Tanabe Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
    Figure 64. Lannett Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
    Figure 65. Bruschettini Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
    Figure 66. Shanghai Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
    Figure 67. Grindeks Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
    Figure 68. Acorda Therapeutics Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
    Figure 69. Gilead Sciences Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
    Figure 70. Intercept Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
    Figure 71. Shire Plc Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
    Figure 72. NGM Biopharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
    Figure 73. Conatus Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
    Figure 74. Durect Corporation Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
    Figure 75. Sirnaomics Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
    Figure 76. Shenzhen HighTide Biopharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
    Figure 77. Bottom-up and Top-down Approaches for This Report
    Figure 78. Data Triangulation
    Figure 79. Key Executives Interviewed